Drugs · acquisition-cost intelligence
Restasis MultiDose
cyclosporine· ingredient cyclosporineCalcineurin inhibitors· CYCLOSPORINE .5 mg/mL
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per ML
$112.33
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per ML — the trend nobody else shows. 6 weeks.
2025-12-172026-05-20
Same-ingredient options by acquisition cost
Other cyclosporine products, cheapest acquisition cost first. Per ML — confirm strength/form equivalence before switching.
| Product | NADAC / ML | vs this |
|---|---|---|
| CycloSPORINE, Modfied | $0.71770 | −$111.62 |
| RESTASIS | $1.52 | −$110.81 |
| Cyclosporine | $2.35 | −$109.98 |
| Cyclosporine | $5.58 | −$106.75 |
| VEVYE | $368.89 | +$256.56 |
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.